CLINICAL TRIALS AND OBSERVATIONS First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia
نویسندگان
چکیده
Barbara F. Eichhorst,1 Raymonde Busch,2 Stephan Stilgenbauer,3 Martina Stauch,4 Manuela A. Bergmann,5 Matthias Ritgen,6 Nicole Kranzhöfer,7 Robert Rohrberg,8 Ulrike Söling,9 Oswald Burkhard,10 Anne Westermann,1 Valentin Goede,1 Carmen D. Schweighofer,1 Kirsten Fischer,1 Anna-Maria Fink,1 Clemens M. Wendtner,1 Günter Brittinger,11 Hartmut Döhner,3 Bertold Emmerich,12 Michael Hallek,1 and the German CLL Study Group (GCLLSG)
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia
Autoimmune hemolytic anemia (AHA) is a common complication in chronic lymphocytic leukemia (CLL). The UK LRF CLL4 trial is the largest prospective trial in CLL to examine the prognostic impact of both a positive direct antiglobulin test (DAT) and AHA. Seven-hundred seventy-seven patients were randomized to receive chlorambucil or fludarabine, alone or with cyclophosphamide (FC). The incidence p...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
Optimal management of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) is dictated by patient characteristics, prior therapy, and response to prior therapy. We report the final analysis of combined fludarabine, cyclophosphamide, and rituximab (FCR) for previously treated patients with CLL and identify patients who benefit most from this therapy. We explore efficacy of FCR in...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)
Tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF) play an important role in the biology of chronic lymphocytic leukemia (CLL) cells. Thalidomide is a first-generation immunomodulating agent that down-regulates TNFand VEGF. We initiated a phase 1/2 clinical trial to determine the safety and efficacy of combining thalidomide with fludarabine in patients with treatmentnaı̈ve...
متن کاملInduction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents.
Phenylacetate (PA) and phenylbutyrate (PB) are aromatic fatty acids that are presently undergoing evaluation as potential antineoplastic agents. In vitro, PA and PB cause differentiation or growth inhibition of malignant cells. Clinical trials of these drugs as single agents indicate that they are not myelosuppressive; therefore, combinations with other chemotherapy agents may be possible. The ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) is associated with superior overall survival (OS) for patients with chronic lymphocytic leukemia (CLL). Alemtuzumab (A) was added to FCR (CFAR) in a phase 2 trial for high-risk untreated patients < 70 years with serum -2 microglobulin ( 2M) > 4 mg/L. Sixty patients were enrolled; median age was 59 years (range,...
متن کامل